Efavirenz, Emtricitabine, and Tenofovir
Efavirenz, emtricitabine and tenofovir disoproxil fumarate is a three-drug combination tablet used to treat HIV-1 infection in adults and children weighing at least 40 kg.
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 7 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
Efavirenz, emtricitabine and tenofovir (Atripla) is a once-daily, three-drug tablet that can treat HIV-1 on its own in adults and children of at least 40 kg, blocking reverse transcriptase (the enzyme HIV uses to copy itself) in two ways; on the market since about 2006 and available generically, it was once a preferred first choice and is now mostly an alternative to newer regimens. Its efavirenz part causes most of the trouble, with dizziness, poor sleep and vivid dreams that usually fade within 2 to 4 weeks. Its boxed warning covers people who also have hepatitis B, whose liver can flare severely if it is stopped, so never stop on your own.
Clinical pearls
- Take it on an empty stomach, ideally at bedtime, so you sleep through much of the early dizziness.
- Get help right away for severe depression, paranoia or suicidal thoughts, or a blistering, peeling rash with mouth sores or fever.
- Use effective contraception and avoid pregnancy during treatment and for 12 weeks after stopping, because efavirenz may harm an early pregnancy.
- Expect kidney and liver blood tests, and limit NSAIDs like ibuprofen, since heavy or combined use adds to tenofovir's kidney risk.
⚠️ FDA Boxed Warning — the FDA’s strongest safety alert ▾
If you have both HIV-1 and hepatitis B and stop this medicine, your hepatitis B can suddenly get much worse. This can be severe and may lead to liver failure.
Do not stop on your own. If you do stop, your doctor should closely check your liver with exams and blood tests for at least several months. You may need hepatitis B treatment.
Patient information guide A plain-language walkthrough of Efavirenz, Emtricitabine, and Tenofovir, written from its FDA label.
What Efavirenz, Emtricitabine, and Tenofovir is used for
▾
This three-drug combination is used for HIV-1 infection.
- Treats HIV-1 infection in adults and pediatric patients weighing at least 40 kg.
- Can be used as a complete regimen or with other antiretroviral medicines.
How Efavirenz, Emtricitabine, and Tenofovir works
▾
This tablet combines three antiviral drugs. Efavirenz is a non-nucleoside reverse transcriptase inhibitor. Emtricitabine and tenofovir disoproxil fumarate are nucleoside analog reverse transcriptase inhibitors. Together they act against HIV-1.
Efavirenz, Emtricitabine, and Tenofovir dosage
▾
Efavirenz, emtricitabine and tenofovir disoproxil fumarate tablets are taken by mouth, one tablet once a day, on an empty stomach.
- Bedtime dosing may make dizziness and other nervous system symptoms easier to handle.
- Your prescriber may adjust the efavirenz amount if you also take rifampin and weigh 50 kg or more.
- Follow your prescriber's directions and the pharmacy label.
Dosing details from the FDA-approved label
From the Efavirenz, Emtricitabine, and Tenofovir prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.
- Adults and pediatric patients weighing at least 40 kg
- One tablet once daily taken orally on an empty stomach, preferably at bedtime (each tablet contains 600 mg of efavirenz, 200 mg of emtricitabine, and 300 mg of tenofovir disoproxil fumarate)
- Dosing at bedtime may improve the tolerability of nervous system symptoms
- Renal impairment (moderate or severe, estimated creatinine clearance below 50 mL/min)
- Not recommended in patients with estimated creatinine clearance below 50 mL/min
- Hepatic impairment (moderate to severe, Child-Pugh B or C)
- Not recommended in patients with moderate to severe hepatic impairment
- Coadministration with rifampin in patients weighing 50 kg or more
- One tablet once daily followed by one additional 200 mg per day of efavirenz
- Applies to patients weighing 50 kg or more
Read the label’s full dosing text
2 DOSAGE AND ADMINISTRATION Testing: Consult Full Prescribing Information for important testing recommendations prior to initiation and during treatment with efavirenz, emtricitabine and tenofovir disoproxil fumarate tablets. ( 2.1 ) Recommended dosage in adults and pediatric patients weighing at least 40 kg: One tablet once daily taken orally on an empty stomach, preferably at bedtime. ( 2.2 ) Renal impairment: Not recommended in patients with estimated creatinine clearance below 50 mL/min. ( 2.3 ) Hepatic impairment: Not recommended in patients with moderate to severe hepatic impairment. ( 2.4 ) Dosage adjustment with rifampin coadministration: An additional 200 mg/day of efavirenz is recommended for patients weighing 50 kg or more. ( 2.5 ) 2.1 Testing Prior to Initiation and During Treatment with Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets Prior to or when initiating efavirenz, emtricitabine and tenofovir disoproxil fumarate tablets, test patients for hepatitis B virus infection [see Warnings and Precautions ( 5.1 )]. Prior to initiation and during use of efavirenz, emtricitabine and tenofovir disoproxil fumarate tablets, on a clinically appropriate schedule, assess serum creatinine, estimated creatinine clearance, urine glucose and urine protein in all patients. In patients with chronic kidney disease, also assess serum phosphorus [see Warnings and Precautions ( 5.7 )]. Monitor hepatic function prior to and during treatment with efavirenz, emtricitabine and tenofovir disoproxil fumarate tablets [see Warnings and Precautions ( 5.3) ] . Perform pregnancy testing before initiation of efavirenz, emtricitabine and tenofovir disoproxil fumarate tablets in adolescents and adults of childbearing potential [see Warnings and Precautions ( 5.8 ), Use in Specific Populations ( 8.1 , 8.3 )]. 2.2 Recommended Dosage for Adults and Pediatric Patients Weighing at Least 40 kg Efavirenz, emtricitabine and tenofovir disoproxil fumarate tablets are a three-drug fixed-dose combination product containing 600 mg of efavirenz (EFV), 200 mg of emtricitabine (FTC), and 300 mg of tenofovir disoproxil fumarate (TDF). The recommended dosage of efavirenz, emtricitabine and tenofovir disoproxil fumarate tablets in adults and pediatric patients weighing at least 40 kg is one tablet once daily taken orally on an empty stomach.
Excerpted — the section continues on the label. Read the full Dosage and Administration section on DailyMed →
Efavirenz, Emtricitabine, and Tenofovir side effects
▾
The most common side effects seen in a clinical trial were:
Common side effects
- Diarrhea
- Nausea
- Fatigue
- Headache
- Dizziness
- Depression
- Trouble sleeping (insomnia)
- Abnormal dreams and rash
When to get medical help
- Call your doctor right away if you have serious mood or mental changes, such as severe depression, thoughts of suicide, aggression, paranoia or hallucinations.
- Stop the medicine and get medical help if you develop a severe rash with blistering, peeling skin, mouth sores or fever.
- Get help if you develop signs of liver problems, as hepatitis and liver failure have been reported.
- Tell your doctor about new or worsening kidney problems.
- Report seizures, especially if you have a history of them.
- Seek care for symptoms of lactic acidosis (a buildup of acid in the blood) or an enlarged liver.
- If you have hepatitis B and stop this medicine, your liver may get much worse, so contact your doctor before stopping.
- Report confusion, unsteady walking or other serious nervous system changes, which can appear months to years after starting.
Efavirenz, Emtricitabine, and Tenofovir warnings and precautions
▾
- Hepatitis B flare: Stopping this medicine can cause severe worsening of hepatitis B in people who have both infections.
- Rash: Usually mild to moderate, but stop the medicine for severe rash with blistering, peeling, mouth sores or fever.
- Liver problems: Hepatitis and liver failure have been reported, including in people without known liver disease.
- Mental health effects: Severe depression, suicidal thoughts, aggression and paranoia have been reported. Seek medical evaluation right away.
- Nervous system symptoms: Dizziness, trouble sleeping and vivid dreams are common and usually improve in 2 to 4 weeks. Late-onset problems can occur.
- Kidneys, bones and seizures: New or worsening kidney problems, bone density loss and seizures can occur.
- Other risks: Lactic acidosis, immune reconstitution syndrome, QTc prolongation and body fat changes.
Efavirenz, Emtricitabine, and Tenofovir interactions
▾
Many medicines can interact with this combination, so review everything you take with your pharmacist.
- Voriconazole and elbasvir/grazoprevir: must not be combined.
- Atazanavir: not recommended.
- Other NNRTIs: not recommended, since efavirenz is already included.
- Rifampin: efavirenz amount may need adjusting.
- Some hepatitis C medicines (glecaprevir/pibrentasvir, simeprevir, sofosbuvir/velpatasvir): not recommended.
- Drugs hard on the kidneys (high-dose or multiple NSAIDs, aminoglycosides, acyclovir and similar): can raise drug levels or kidney risk.
- Drugs that affect heart rhythm: alternatives should be considered.
- Anticonvulsants, warfarin, bupropion, sertraline and some antifungals: levels may change.
Interactions listed in the FDA-approved label
From the Efavirenz, Emtricitabine, and Tenofovir prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.
- Atazanavir or atazanavir/ritonavir: Decreases atazanavir and increases tenofovir; the combined effect of EFV plus TDF on atazanavir concentrations is not known. Coadministration is not recommended.
- Lopinavir/ritonavir or darunavir/ritonavir: Increases tenofovir concentrations (lopinavir also decreased). Monitor for tenofovir toxicity/TDF-associated adverse reactions and discontinue if they develop. Do not use once daily lopinavir/ritonavir; a lopinavir/ritonavir dose increase is recommended when coadministered with EFV.
- Ritonavir: Ritonavir 500 mg every 12 hours with EFV 600 mg once daily was associated with higher frequency of adverse clinical experiences (e.g., dizziness, nausea, paresthesia) and elevated liver enzymes. Monitoring of liver enzymes is recommended.
- Didanosine: Increases didanosine concentrations, which could potentiate adverse reactions including pancreatitis and neuropathy; CD4+ suppression observed with TDF and didanosine 400 mg daily. Monitor closely and discontinue didanosine if adverse reactions develop. Reduce didanosine dose to 250 mg in patients weighing greater than 60 kg and to 200 mg in patients weighing less than 60 kg.
- Other NNRTIs: May raise or lower efavirenz and/or the NNRTI; combining two NNRTIs has not been shown to be beneficial. Should not be coadministered with other NNRTIs.
- Elbasvir/grazoprevir: Decreases elbasvir and grazoprevir and may lead to loss of virologic response. Coadministration is contraindicated.
- Glecaprevir/pibrentasvir, simeprevir, sofosbuvir/velpatasvir, sofosbuvir/velpatasvir/voxilaprevir: Decreases concentrations of the hepatitis C agents and may reduce therapeutic effect. Coadministration is not recommended.
- Drugs eliminated by active tubular secretion or that decrease renal function (e.g., acyclovir, cidofovir, ganciclovir, aminoglycosides, high-dose or multiple NSAIDs): May increase concentrations of FTC, tenofovir, and/or the coadministered drug.
- Carbamazepine: Decreases carbamazepine and efavirenz. Insufficient data for a dose recommendation; alternative anticonvulsant treatment should be used.
- Drugs with a known risk of Torsade de Pointes: QTc prolongation has been observed with EFV. Consider alternatives to the tablets when coadministered.
Read the label’s full interactions text
7 DRUG INTERACTIONS Consult Full Prescribing Information prior to and during treatment for important potential drug interactions. ( 4 , 5.4 , 7 ) HIV-1 protease inhibitors: Coadministration of efavirenz, emtricitabine and tenofovir disoproxil fumarate tablets with either lopinavir/ritonavir or darunavir and ritonavir increases tenofovir concentrations. Monitor for evidence of tenofovir toxicity. Coadministration of efavirenz, emtricitabine and tenofovir disoproxil fumarate tablets with either atazanavir or atazanavir and ritonavir is not recommended. ( 7.3 ) 7.1 Efavirenz Efavirenz has been shown in vivo to induce CYP3A and CYP2B6. Other compounds that are substrates of CYP3A or CYP2B6 may have decreased plasma concentrations when coadministered with EFV. Drugs that induce CYP3A activity (e.g., phenobarbital, rifampin, rifabutin) would be expected to increase the clearance of EFV, resulting in lowered plasma concentrations [see Dosage and Administration ( 2.2 )] . There is limited information available on the potential for a pharmacodynamic interaction between EFV and drugs that prolong the QTc interval. QTc prolongation has been observed with the use of EFV [see Clinical Pharmacology ( 12.2 )] . Consider alternatives to efavirenz, emtricitabine and tenofovir disoproxil fumarate tablets when coadministered with a drug with a known risk of Torsade de Pointes. 7.2 Drugs Affecting Renal Function FTC and tenofovir are primarily eliminated by the kidneys [see Clinical Pharmacology ( 12.3 )] . Coadministration of efavirenz, emtricitabine and tenofovir disoproxil fumarate tablets with drugs that are eliminated by active tubular secretion may increase concentrations of FTC, tenofovir, and/or the coadministered drug. Some examples include, but are not limited to, acyclovir, adefovir dipivoxil, cidofovir, ganciclovir, valacyclovir, valganciclovir, aminoglycosides (e.g., gentamicin), and high-dose or multiple NSAIDs [see Warnings and Precautions ( 5.7 )] .
Excerpted — the section continues on the label. Read the full Drug Interactions section on DailyMed →
Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.
Before taking Efavirenz, Emtricitabine, and Tenofovir
▾
- Do not take it if you have had a serious hypersensitivity reaction to efavirenz.
- Get tested for hepatitis B before starting.
- Not recommended with moderate to severe kidney impairment (creatinine clearance below 50 mL/min).
- Not recommended with moderate to severe liver impairment.
- Avoid pregnancy during treatment and for 12 weeks after stopping. Pregnancy testing and effective contraception are advised.
- Breastfeeding is not recommended.
- Rash was more common in children than in adults.
- Tell your doctor about seizures, mental health history, or bone fracture or osteoporosis risk.
Efavirenz, Emtricitabine, and Tenofovir overdose
▾
If too much is taken, you should be monitored for signs of toxicity and given supportive care. Some people who accidentally took efavirenz twice daily had stronger nervous system symptoms, and one had involuntary muscle contractions. Activated charcoal may help remove unabsorbed efavirenz. Dialysis can remove emtricitabine and tenofovir but is unlikely to remove much efavirenz.
What Efavirenz, Emtricitabine, and Tenofovir does in the body
▾
Efavirenz can lengthen the QTc interval (a measure of heart rhythm), and higher efavirenz levels were linked to greater lengthening. This effect was larger in people with a certain CYP2B6 gene type, who have higher efavirenz levels.
How your body processes Efavirenz, Emtricitabine, and Tenofovir
▾
One tablet is bioequivalent to taking efavirenz, emtricitabine and tenofovir disoproxil fumarate as separate products. Efavirenz peaks in about 3 to 5 hours, is broken down by liver enzymes (CYP3A and CYP2B6) and has a long half-life of roughly 40 to 76 hours. Emtricitabine and tenofovir are cleared mainly by the kidneys, with half-lives of about 10 and 17 hours. A high-fat meal raised efavirenz levels, which is why the tablet is taken on an empty stomach.
How to store Efavirenz, Emtricitabine, and Tenofovir
▾
Store at 25°C (77°F); excursions permitted to 15°C –30°C (59°F –86°F) .
Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
Efavirenz, Emtricitabine, and Tenofovir: pharmacist answers to common questions
Quick, plain-English answers to the questions patients ask most about Efavirenz, Emtricitabine, and Tenofovir — the kind of thing our pharmacy team would talk through with you at the counter.
What is this medicine for?
▾
How and when should I take it?
▾
What side effects should I expect?
▾
Can I stop it if I feel fine?
▾
Is it safe in pregnancy?
▾
Do I need to worry about other medicines?
▾
Is Efavirenz, Emtricitabine, and Tenofovir available over the counter?
▾
When was Efavirenz, Emtricitabine, and Tenofovir first available?
▾
Who makes Efavirenz, Emtricitabine, and Tenofovir?
▾
Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
More about Efavirenz, Emtricitabine, and Tenofovir on HelloPharmacist
Efavirenz, Emtricitabine, and Tenofovir forms and strengths (how it comes)
Efavirenz, Emtricitabine, and Tenofovir is available in 1 form. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Efavirenz, Emtricitabine, and Tenofovir inactive ingredients by manufacturer.
Tablet
How this form is used
- Efavirenz, emtricitabine and tenofovir disoproxil fumarate tablets are used for HIV-1 infection in adults and pediatric patients weighing at least 40 kg.
- Efavirenz, emtricitabine and tenofovir disoproxil fumarate tablets are taken as one tablet by mouth once daily on an empty stomach.
- Bedtime dosing of efavirenz, emtricitabine and tenofovir disoproxil fumarate tablets may improve tolerability of nervous system symptoms.
Efavirenz, Emtricitabine, and Tenofovir on the U.S. market: products, makers and brands
How Efavirenz, Emtricitabine, and Tenofovir appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
7 companies list 7 Efavirenz, Emtricitabine, and Tenofovir product records with the FDA, mostly as tablet; the earliest marketing or approval year on record is 2006. Brand names on the directory include Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate; the rest are generics.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
How widely Efavirenz, Emtricitabine, and Tenofovir is used (Medicaid data)
A general measure of how commonly Efavirenz, Emtricitabine, and Tenofovir is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Efavirenz, Emtricitabine, and Tenofovir is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Efavirenz, Emtricitabine, and Tenofovir prescribed? Of the 1,601 medications we measure, Efavirenz, Emtricitabine, and Tenofovir ranks #1,076 by Medicaid prescriptions — more than 33% of them.
Utilization by Efavirenz, Emtricitabine, and Tenofovir product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
efavirenz 600 MG / emtricitabine 200 MG / tenofovir disoproxil fumarate 300 MG Oral Tablet
Summed across the 5 of 13 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 643066
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Efavirenz, Emtricitabine, and Tenofovir, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 5 of 13 listed Efavirenz, Emtricitabine, and Tenofovir NDCs with Medicaid activity.
Compare Efavirenz, Emtricitabine, and Tenofovir products
A representative set of FDA-listed product records for Efavirenz, Emtricitabine, and Tenofovir — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Tablet | ||||
| EFAVIRENZ 600 mg/1; EMTRICITABINE 200 mg/1; TENOFOVIR DISOPROXIL FUMARATE 300 mg | Oral | Aurobindo Pharma Limited | ANDA | View NDC → |
| EFAVIRENZ 600 mg/1; EMTRICITABINE 200 mg/1; TENOFOVIR DISOPROXIL FUMARATE 300 mg | Oral | Bryant Ranch Prepack | ANDA | View NDC → |
| EFAVIRENZ 600 mg/1; EMTRICITABINE 200 mg/1; TENOFOVIR DISOPROXIL FUMARATE 300 mg | Oral | Camber Pharmaceuticals, Inc. | ANDA | View NDC → |
| EFAVIRENZ 600 mg/1; EMTRICITABINE 200 mg/1; TENOFOVIR DISOPROXIL FUMARATE 300 mg | Oral | Cipla USA Inc. | ANDA | View NDC → |
| EFAVIRENZ 600 mg/1; EMTRICITABINE 200 mg/1; TENOFOVIR DISOPROXIL FUMARATE 300 mg | Oral | Laurus Labs Limited | ANDA | View NDC → |
| EFAVIRENZ 600 mg/1; EMTRICITABINE 200 mg/1; TENOFOVIR DISOPROXIL FUMARATE 300 mg | Oral | Macleods Pharmaceuticals Limited | ANDA | View NDC → |
| EFAVIRENZ 600 mg/1; EMTRICITABINE 200 mg/1; TENOFOVIR DISOPROXIL FUMARATE 300 mg | Oral | Teva Pharmaceuticals USA, Inc. | ANDA | View NDC → |
Showing 7 of 7 products — FDA National Drug Code Directory. See every product, package size and price: browse all 7 Efavirenz, Emtricitabine, and Tenofovir NDCs →
Efavirenz, Emtricitabine, and Tenofovir side effects reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Efavirenz, Emtricitabine, and Tenofovir — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Efavirenz, Emtricitabine, and Tenofovir in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
Efavirenz, Emtricitabine, and Tenofovir FDA approval history
How Efavirenz, Emtricitabine, and Tenofovir went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
Efavirenz, Emtricitabine, and Tenofovir recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
The FDA’s enforcement reports list no Efavirenz, Emtricitabine, and Tenofovir recalls since July 2021.
✅No Efavirenz, Emtricitabine, and Tenofovir recalls on record since July 2021Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Sep 24, 2026.
Efavirenz, Emtricitabine, and Tenofovir supply and shortage status
Whether Efavirenz, Emtricitabine, and Tenofovir is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
💵 What Efavirenz, Emtricitabine, and Tenofovir costs pharmacies (NADAC benchmark)
The national average invoice price pharmacies pay for the drug itself, from CMS's NADAC survey (data as of Sep 30, 2026). This is a supply-cost benchmark — not a retail price and not what you'd pay at the counter.
| Form | Strength | Pharmacy acquisition benchmark | |
|---|---|---|---|
| Tablet, Film Coated · Oral | EFAVIRENZ 600 mg/1; EMTRICITABINE 200 mg/1; TENOFOVIR DISOPROXIL FUMARATE 300 mg | $1.12 per tablet | NDC details & price history |
| Tablet, Film Coated · Oral | 600; 200; 300 mg/1; mg/1; mg | $1.12 per tablet | NDC details & price history |
Source: CMS National Average Drug Acquisition Cost (NADAC), a survey of retail pharmacy invoice prices. Benchmarks shown are the range across package sizes of a representative product for each form and strength — other manufacturers' products may differ.
Efavirenz, Emtricitabine, and Tenofovir brand names
Efavirenz, Emtricitabine, and Tenofovir is sold under one brand name in the FDA directory — Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.
Who makes Efavirenz, Emtricitabine, and Tenofovir: manufacturers and labelers
7 companies list Efavirenz, Emtricitabine, and Tenofovir products with the FDA. By number of product records, the largest are Aurobindo Pharma Limited, Bryant Ranch Prepack, Camber Pharmaceuticals, Inc.. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.
Efavirenz, Emtricitabine, and Tenofovir drug class (RxNorm)
Efavirenz, Emtricitabine, and Tenofovir belongs to the Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
Sources for this Efavirenz, Emtricitabine, and Tenofovir page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How this page is built
HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Teva Pharmaceuticals USA, Inc. is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →